Outcomes of human leukocyte antigen-matched allogeneic cultivated limbal epithelial transplantation in aniridia-associated keratopathy - a single-center retrospective analysis

Behaegel, Joséphine ; Tassignon, María José ; Lagali, Neil ; Consejo, Alejandra (Universidad de Zaragoza) ; Koppen, Carina ; Ni Dhubhghaill, Sorcha

Resumen: To assess the efficacy and safety of human leukocyte antigen-matched allogeneic cultivated limbal epithelial stem cell grafts in the treatment of aniridia-associated keratopathy (AAK). Methods: Six eyes of 6 patients with severe AAK received an allogeneic stem cell graft between January 2010 and March 2017. Anatomical and functional results were assessed at 6 months, 1 year, 2 years, and the final follow-up visit available. Safety analysis was performed by considering all perioperative and postoperative adverse events and additional surgeries required during the follow-up period.Results:The mean follow-up was 53.6 months (range 24-104 months). In most patients (80%), there was an early improvement of the keratopathy postoperatively, which slowly regressed during longer follow-up. At the final follow-up, 4 of the eyes were graded as failure and 1 eye was graded as partial success. Grading the sixth eye was not possible because of an adverse event. None of the patients maintained a total anatomical success in the long-term. Only 1 patient maintained a modest improvement in best-corrected visual acuity from hand motion to counting fingers. Four serious adverse events were recorded in 2 patients.Conclusions:Severe AAK remains a challenging condition to manage. Transplantation of allogenic ex vivo cultivated limbal stem cells may provide a temporary improvement in ocular surface stability, but anatomical and functional results are poor in the long-term. The eyes are prone to adverse events, and any surgical treatment should take this into consideration.

Idioma: Inglés

DOI: 10.1097/ICO.0000000000002729

Año: 2022

Publicado en: CORNEA 41, 1 (2022), 69-77
ISSN: 0277-3740

Factor impacto JCR: 2.8 (2022)

Categ. JCR: OPHTHALMOLOGY rank: 26 / 62 = 0.419 (2022) - Q2 - T2

Factor impacto CITESCORE: 4.9 - Medicine (Q2)

Factor impacto SCIMAGO: 0.968 - Ophthalmology (Q1)

Financiación: info:eu-repo/grantAgreement/EC/H2020/667400 /EU/Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS/ARREST BLINDNESS

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Física Aplicada (Dpto. Física Aplicada)